Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ivabradine

- PMLiVE

Amgen wins FDA approval for cholesterol drug Repatha

Willgive it a quick launch in the US to catch-up with Sanofi's Praluent

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

- PMLiVE

Amgen beats Sanofi to PCSK9 inhibitor market

EC approval for Repatha gives it a lead over Praluent

- PMLiVE

Amgen’s Blincyto effective in broader leukaemia population

Could lead to further licences for the $178,000 blood cancer treatment

- PMLiVE

Novartis gets early approval for heart failure drug Entresto

It is the first worldwide indication for the in-class neprilysin inhibitor

- PMLiVE

Vertex wins FDA approval for cystic fibrosis therapy Orkambi

It is the combination therapy’s first regulatory approval

Novartis day

Novartis heart drug may see novel pricing plan

Swiss firm looking to risk share with payers based on clinical outcomes

- PMLiVE

Generic Copaxone launches in US

Sandoz and Momenta Pharmaceuticals started shipping Glatopa in reaction

- PMLiVE

Novartis gets FDA nod for rare blood disorder drug

Promacta will provide a treatment option for children over 6 years old

- PMLiVE

FDA approves brain implant for Parkinson’s disease

The Brio Neurostimulation System also found to improve essential tremor

- PMLiVE

Praluent and Repatha backed for approval in US

Sanofi and Amgen remain in fierce competition in PCSK9 inhibitors

Sanofi reception

Sanofi and Amgen poised for cholesterol drug sales

Praluent to be assessed by FDA advisory committee later this week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links